Treatment of Neuroleptic Induced Acute Akathisia With Trazodone

BeerYaakov Mental Health Center

Status and phase: Completed; Phase 4

Conditions: Schizophrenia

Treatments: Drug: Placebo; Drug: Trazodone

Study type: Interventional

Funder types: Other

Identifiers

NCT00659919

Trazodone-60CTIL

Details and patient eligibility

About

Administration of trazodone for the treatment of neuroleptic induced acute akathisia in a cross-over fashion of 6 days duration. 3 days of placebo and 3 days of trazodone.

Enrollment: 13 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with akathisia according to DSM-IV criteria at least mild akathisia.

Exclusion criteria

• Change of pharmacologic regimen 7 days prior to study entry
• Significant systemic disease
• The presence of chronic akathisia
• Patients unable to cooperate

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

13 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

The patients in this arm received placebo

Treatment:

Drug: Placebo

Trazodone

Active Comparator group

Description:

The patients on this arm received Trazodone for 3 consecutive days

Treatment:

Drug: Trazodone